BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hasegawa I, Orito E, Tanaka Y, Hirashima N, Sakakibara K, Sakurai M, Suzuki S, Sugauchi F, Ohno T, Ueda R. Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C. Liver Int. 2005;25:247-253. [PMID: 15780046 DOI: 10.1111/j.1478-3231.2005.1096.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Chu CJ, Lee SD. Occult hepatitis B virus infection in patients with chronic hepatitis C: An actor behind the scene or just a bystander? J Gastroenterol Hepatol 2010;25:221-3. [PMID: 20136983 DOI: 10.1111/j.1440-1746.2009.06134.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
2 Midorikawa Y, Takayama T, Nakayama H, Higaki T, Moriguchi M, Moriya K, Kanda T, Matsuoka S, Moriyama M. Prior hepatitis B virus infection as a co-factor of chronic hepatitis C patient survival after resection of hepatocellular carcinoma. BMC Gastroenterol 2019;19:147. [PMID: 31426746 DOI: 10.1186/s12876-019-1069-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Coppola N, Onorato L, Sagnelli C, Sagnelli E, Angelillo IF. Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis. Medicine (Baltimore). 2016;95:e4311. [PMID: 27472708 DOI: 10.1097/md.0000000000004311] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
4 Carvalho-Filho RJ, de Lucca Schiavon L, Narciso-Schiavon JL, Sampaio JP, Lanzoni VP, Gomes Ferraz ML, Benedito Silva AE. Clinical and histological impact of previous hepatitis B virus infection in patients with chronic hepatitis C. Liver Int. 2009;29:133-140. [PMID: 18507759 DOI: 10.1111/j.1478-3231.2008.01786.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
5 Chen G, Wang C, Chen J, Ji D, Wang Y, Wu V, Karlberg J, Lau G. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. Hepatology. 2017;66:13-26. [PMID: 28195337 DOI: 10.1002/hep.29109] [Cited by in Crossref: 96] [Cited by in F6Publishing: 85] [Article Influence: 24.0] [Reference Citation Analysis]
6 Coppola N, Onorato L, Pisaturo M, Macera M, Sagnelli C, Martini S, Sagnelli E. Role of occult hepatitis B virus infection in chronic hepatitis C. World J Gastroenterol 2015; 21(42): 11931-11940 [PMID: 26576082 DOI: 10.3748/wjg.v21.i42.11931] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
7 Chen LW, Chien RN, Yen CL, Chang JJ, Liu CJ, Lin CL. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection. J Gastroenterol Hepatol. 2010;25:259-263. [PMID: 19817959 DOI: 10.1111/j.1440-1746.2009.06006.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
8 Yamaji K, Kai K, Komukai S, Koga H, Ide T, Kawaguchi A, Noshiro H, Aishima S. Occult HBV infection status and its impact on surgical outcomes in patients with curative resection for HCV-associated hepatocellular carcinoma. Hepatobiliary Surg Nutr 2018;7:443-53. [PMID: 30652089 DOI: 10.21037/hbsn.2018.10.01] [Reference Citation Analysis]
9 Potthoff A, Manns MP, Wedemeyer H. Treatment of HBV/HCV coinfection. Expert Opin Pharmacother. 2010;11:919-928. [PMID: 20166841 DOI: 10.1517/14656561003637659] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
10 Bal T, Onlen Y. The prevalence of occult hepatitis B in chronic hepatitis C patients treated with interferon-based antiviral therapy. Arab J Gastroenterol 2018;19:33-6. [PMID: 29503077 DOI: 10.1016/j.ajg.2018.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Fernandez-Rodriguez CM, Gutierrez ML, Lledó JL, Casas ML. Influence of occult hepatitis B virus infection in chronic hepatitis C outcomes. World J Gastroenterol 2011; 17(12): 1558-1562 [PMID: 21472121 DOI: 10.3748/wjg.v17.i12.1558] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
12 Cardoso C, Alves AL, Augusto F, Freire R, Quintana C, Gonçalves M, Oliveira AP. Occult hepatitis B infection in Portuguese patients with chronic hepatitis C liver disease: prevalence and clinical significance. Eur J Gastroenterol Hepatol. 2013;25:142-146. [PMID: 23044809 DOI: 10.1097/meg.0b013e328359fe54] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
13 Alavian SM, Miri SM, Hollinger FB, Jazayeri SM. Occult Hepatitis B (OBH) in Clinical Settings. Hepat Mon 2012;12:e6126. [PMID: 23087749 DOI: 10.5812/hepatmon.6126] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
14 Reddy A, May E, Ehrinpreis M, Mutchnick M. Latent hepatitis B is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C. World J Gastroenterol 2013; 19(48): 9328-9333 [PMID: 24409059 DOI: 10.3748/wjg.v19.i48.9328] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
15 Jiang XW, Ye JZ, Li YT, Li LJ. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. World J Gastroenterol 2018; 24(28): 3181-3191 [PMID: 30065564 DOI: 10.3748/wjg.v24.i28.3181] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
16 Habibollahi P, Safari S, Daryani NE, Alavian SM. Occult hepatitis B infection and its possible impact on chronic hepatitis C virus infection. Saudi J Gastroenterol. 2009;15:220-224. [PMID: 19794265 DOI: 10.4103/1319-3767.56089] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
17 Jamma S, Hussain G, Lau DT. Current Concepts of HBV/HCV Coinfection: Coexistence, but Not Necessarily in Harmony. Curr Hepat Rep 2010;9:260-9. [PMID: 21258658 DOI: 10.1007/s11901-010-0060-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
18 Nishikawa H, Osaki Y. Clinical significance of occult hepatitis B infection in progression of liver disease and carcinogenesis. J Cancer 2013;4:473-80. [PMID: 23901347 DOI: 10.7150/jca.6609] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
19 Tsubouchi N, Uto H, Kumagai K, Sasaki F, Kanmura S, Numata M, Moriuchi A, Oketani M, Ido A, Hayashi K. Impact of antibody to hepatitis B core antigen on the clinical course of hepatitis C virus carriers in a hyperendemic area in Japan: A community-based cohort study. Hepatol Res. 2013;43:1130-1138. [PMID: 23413835 DOI: 10.1111/hepr.12075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
20 Miura Y, Shibuya A, Adachi S, Takeuchi A, Tsuchihashi T, Nakazawa T, Saigenji K. Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails. Hepatol Res. 2008;38:546-556. [PMID: 18179561 DOI: 10.1111/j.1872-034x.2007.00316.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
21 Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, Chen Z. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int. 2012;32:231-240. [PMID: 21745272 DOI: 10.1111/j.1478-3231.2011.02481.x] [Cited by in Crossref: 84] [Cited by in F6Publishing: 87] [Article Influence: 8.4] [Reference Citation Analysis]
22 Cho J, Lee SS, Choi YS, Jeon Y, Chung JW, Baeg JY, Si WK, Jang ES, Kim JW, Jeong SH. Occult hepatitis B virus infection is not associated with disease progression of chronic hepatitis C virus infection. World J Gastroenterol 2016; 22(42): 9427-9436 [PMID: 27895431 DOI: 10.3748/wjg.v22.i42.9427] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
23 Tanaka K. Does occult hepatitis B virus infection cause hepatocellular carcinoma in patients with chronic liver disease related to hepatitis C virus? Hepatology Research 2008;38:543-5. [DOI: 10.1111/j.1872-034x.2008.00350.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Georgiadou SP, Zachou K, Liaskos C, Gabeta S, Rigopoulou EI, Dalekos GN. Occult hepatitis B virus infection in patients with autoimmune liver diseases. Liver International 2009;29:434-42. [DOI: 10.1111/j.1478-3231.2008.01851.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
25 Stratta P, Bruschetta E, Minisini R, Barbè MC, Cornella C, Tognarelli G, Cena T, Magnani C, Fenoglio R, Toffolo K, Airoldi A, Pirisi M. Prevalence and clinical relevance of occult hepatitis B virus infection in patients on the waiting list for kidney transplantation. Transplant Proc 2009;41:1132-7. [PMID: 19460498 DOI: 10.1016/j.transproceed.2009.03.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
26 Huang X, Hollinger FB. Occult hepatitis B virus infection and hepatocellular carcinoma: a systematic review. J Viral Hepat. 2014;21:153-162. [PMID: 24438677 DOI: 10.1111/jvh.12222] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 6.9] [Reference Citation Analysis]